Quarterly procedure volume updates and HEPZATO KIT unit sales - the primary commercial traction metric
Reimbursement milestones including CMS coverage decisions, J-code assignments, and private payer policies
Clinical data releases from ongoing studies or real-world evidence supporting efficacy and safety
Cash runway updates and financing announcements given negative operating cash flow
low - Healthcare spending, particularly for life-threatening cancers with limited alternatives, demonstrates minimal correlation to GDP cycles. Uveal melanoma patients and oncologists make treatment decisions based on clinical need rather than economic conditions. However, hospital capital budgets for new procedural technologies can face pressure during recessions, potentially slowing adoption rates at new centers.
Rising interest rates create moderate headwinds through two channels: (1) Higher discount rates compress valuation multiples for pre-profitable biotech/medtech companies with cash flows years in the future, and (2) Increased financing costs for future capital raises needed to fund operations until profitability. The company's minimal debt (0.01 D/E) limits direct interest expense impact, but equity dilution risk increases when raising capital in higher-rate environments. Conversely, falling rates support valuation expansion and cheaper financing access.
Reimbursement uncertainty - CMS and private payers may establish inadequate reimbursement rates or restrictive coverage policies that limit commercial viability despite FDA approval
Limited patient population - Metastatic uveal melanoma affects approximately 400-500 newly diagnosed US patients annually, creating a small addressable market that may not support standalone profitability without label expansion
Procedural adoption barriers - PHP requires specialized interventional radiology skills and infrastructure not available at all cancer centers, limiting geographic penetration
growth - The stock attracts speculative growth investors and biotech specialists willing to accept binary risk/reward profiles. With 1,701% revenue growth (off minimal base), negative profitability, and early commercialization stage, the investment thesis centers on successful commercial execution and potential label expansion creating multi-year revenue growth runway. The -42.6% one-year return and high volatility reflect typical pre-profitable specialty pharma trading dynamics. Not suitable for value or income investors given negative cash flows and no dividend. Momentum traders may engage around clinical/regulatory catalysts.
Trend
+12.2% vs SMA 50 · +5.0% vs SMA 200
Momentum
Volume distribution is neutral or leaning toward distribution. No compelling squeeze setup based on current money flow data.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANALYST ESTIMATES
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $85.1M $82.5M–$88.7M | — | $0.05 | — | ±5% | Moderate3 |
FY2026(current) | $103.9M $100.7M–$108.3M | ▲ +22.1% | -$0.56 | — | ±5% | Moderate4 |
FY2027 | $134.3M $130.2M–$140.1M | ▲ +29.3% | -$0.38 | — | ±5% | Moderate4 |
INSTITUTIONAL OWNERSHIP
DCTH News
About
delcath systems, inc. (nasdaq- dcth) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. our proprietary product---melphalan hydrochloride for injection for use with the delcath hepatic delivery system (melphalan/hds)---is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure. delcath is in late-stage clinical development in the united states with initial commercial activities in europe, where the melphalan/hds is marketed as a ce marked device under the trade name delcath hepatic chemosat® delivery system for melphalan (chemosat). our commercial strategy for chemosat is to steadily grow clinical adoption in major european markets and utilize physician experience to support appeals for reimbursement. since launch over 250 chemosat treatments have been performed at over 20 leading european cancer centers. in 2016, we launched our focus pivotal study in hepatic dominant ocular
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
DCTH◀ | $11.07 | -3.40% | $382M | — | +12908.5% | 316.8% | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.96% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -3.12% | — | 50.3 | +343693.9% | -3456.7% | 1500 |